Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics
Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Rhythm Biosciences and datma join forces to validate cancer risk tools with federated data
Rhythm Biosciences Ltd and United States-based federated data platform company datma have announced a strategic exploratory collaboration aimed at validating and scaling genomic-integrated cancer risk prediction through real-world clinical datasets. The partnership centers around the use of datma.FED, a privacy-preserving federated data platform, to evaluate the clinical utility and performance of Rhythm Biosciences’ geneType risk